¥Û¡¼¥à ¡ä°åÎÅ´Ø·¸¼Ô¤ÎÊý¤Ø ¡äÃø½ñ¡¦³Ø²ñ¡¦ÏÀʸ
Ãø½ñ¡¦³Ø²ñ¡¦ÏÀʸ
ÅöÈøÆ»Áí¹çɱ¡¡¢¤ª¤è¤Ó³Æ°å»Õ¤Ë¤è¤Ã¤Æȯɽ¤µ¤ì¤¿Ãø½ñ¡¢³Ø²ñ¤Ç¤ÎȯɽÏÀʸ¤Ê¤É¤ò¸ø³«¤·¤Æ¤¤¤Þ¤¹¡£

[ ¸ÆµÛ´ïÆâ²Ê ] ¤Ë¤è¤ëÃø½ñ¡¦³Ø²ñ¡¦ÏÀʸ
¡ÖÃø½ñ¡×¡Ö³Ø²ñ¡×¡ÖÏÀʸ¡×¤ÎʬÌî¤Ëʬ¤«¤ì¤Æ¤¤¤Þ¤¹¡£¤´´õ˾¤ÎʬÌî¤ò¥¯¥ê¥Ã¥¯¤¹¤ë¤È°ìÍ÷¤¬É½¼¨¤µ¤ì¤Þ¤¹¡£

¹¹¿·Æü¡§2025/02/21
¿ÇÎÅ²Ê | ¸ÆµÛ´ïÆâ²Ê |
ǯ | 2024 |
ÏÀʸ¥¿¥¤¥È¥ë | Ç٤γÈÄ¥¾ã³²¤òÄ褷¤¿¶»Ë쥢¥ß¥í¥¤¥É¡¼¥·¥¹¤Î£±Îã |
»¨»ï¥¿¥¤¥È¥ë | ÆüËܸƵ۴ï³Ø²ñ»ï¡¤13 |
¥Ú¡¼¥¸ÈÖ¹æ | 83-87 |
Ãø¼Ô | ³ÑËÜ¿µ¼£ |
¶¦Ãø | ¼ÂÌÊ¡¡·Ä¡¤Â¿ÅÄ¿µÊ¿¡¤Ë̸¶ÎÉÍΡ¤¿·Ã«µ®ÍΡ¤¹â³¸¼÷ϯ |
¹¹¿·Æü¡§2025/02/21
¿ÇÎÅ²Ê | ¸ÆµÛ´ïÆâ²Ê |
ǯ | 2023 |
ÏÀʸ¥¿¥¤¥È¥ë | Dose reduction of docetaxel avoids the usage of pegfilgrastim in docetaxel plus ramucirumab therapy for recurrent nonsmall cell lung cancer |
»¨»ï¥¿¥¤¥È¥ë | Cancer Rep¡¤6¡Ê4¡Ë |
¥Ú¡¼¥¸ÈÖ¹æ | e1793 |
Ãø¼Ô | Hamai K |
¶¦Ãø | Miyake S¡¤Tada S¡¤Fujita S¡¤Hirakawa T¡¤Matsumura M¡¤Ueno S¡¤Tanimoto T¡¤Ishikawa N |
¹¹¿·Æü¡§2025/02/21
¿ÇÎÅ²Ê | ¸ÆµÛ´ïÆâ²Ê |
ǯ | 2023 |
ÏÀʸ¥¿¥¤¥È¥ë | Comprehensive genomic profiling of Japanese patients with thoracic malignancies¡§A single-center retrospective study |
»¨»ï¥¿¥¤¥È¥ë | Respir Investig¡¤61¡Ê6¡Ë |
¥Ú¡¼¥¸ÈÖ¹æ | 746-754 |
Ãø¼Ô | Hirakawa T |
¶¦Ãø | Doi M¡¤Hamai K¡¤Katsura R¡¤Miyake S¡¤Fujita S¡¤Ueno S¡¤Masuda K¡¤Tanimoto T¡¤Nishisaka T¡¤ Hinoi T¡¤Hirasawa A¡¤Ishikawa N |
¹¹¿·Æü¡§2025/02/21
¿ÇÎÅ²Ê | ¸ÆµÛ´ïÆâ²Ê |
ǯ | 2023 |
ÏÀʸ¥¿¥¤¥È¥ë | Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer |
»¨»ï¥¿¥¤¥È¥ë | Sci Rep¡¤13¡Ê1¡Ë |
¥Ú¡¼¥¸ÈÖ¹æ | 19729 |
Ãø¼Ô | Masuda T |
¶¦Ãø | Miura S¡¤Sato Y¡¤Tachihara M¡¤Bessho A¡¤Nakamura A¡¤Miyawaki T¡¤Yoshimine K¡¤Mori M¡¤ Shiraishi H¡¤Hamai K¡¤Haratani K¡¤Maeda S¡¤Tabata E¡¤Kitagawa C¡¤Tanizaki J¡¤Imai T¡¤Nogami S¡¤ Yamamoto N¡¤Nakagawa K¡¤Hattori N |
¹¹¿·Æü¡§2023/12/29
¿ÇÎÅ²Ê | ¸ÆµÛ´ïÆâ²Ê |
ǯ | 2022 |
ÏÀʸ¥¿¥¤¥È¥ë | µÞÀ¤Î·Ð²á¤Ç»àË´¤·¤¿µÞÀ´Ö¼ÁÇÙ±ê¤Î°ìÎã |
»¨»ï¥¿¥¤¥È¥ë | ¸üÀ¸Ï¢ÈøÆ»Áí¹çɱ¡°åÊó¡¥32 |
¥Ú¡¼¥¸ÈÖ¹æ | 35-39 |
Ãø¼Ô | º¬ËÜÍÛºÚ |
¶¦Ãø | ËÌÅçÂóÇÏ¡¤ËÌÅç¿¿µª»Ò¡¤Ìî¼¹¸À¸¡¤Àîºê¹Ê¿¡¤ÎëÌÚÊþ»Ò¡¤ÊƸ¶½¤¼£¡¤À¾Åĸ»Ê¡¥ |
¹¹¿·Æü¡§2023/12/29
¿ÇÎÅ²Ê | ¸ÆµÛ´ïÆâ²Ê |
ǯ | 2022 |
ÏÀʸ¥¿¥¤¥È¥ë | ¿ÕÀ¸¸¡¤¬¿ÇÃǤηÀµ¡¤È¤Ê¤Ã¤Æ¥¨¥Á¥ì¥ó¥°¥ê¥³¡¼¥ëÃæÆǤΣ±Îã |
»¨»ï¥¿¥¤¥È¥ë | ¹Åç°å³Ø¡¥73(7) |
¥Ú¡¼¥¸ÈÖ¹æ | 299-302 |
Ãø¼Ô | ²¬ÅèÎÜÆà |
¶¦Ãø | »³ËÜæÆÂÀϺ¡¤»³ËÜÎÃÂÀϺ¡¤ÏÆËÜ¡¡°°¡¤Ç÷ͧµª»Ò¡¤ |
¹¹¿·Æü¡§2023/12/29
¿ÇÎÅ²Ê | ¸ÆµÛ´ïÆâ²Ê |
ǯ | 2022 |
ÏÀʸ¥¿¥¤¥È¥ë | Association Between Patient Preference for Inhaler Medications and Asthma Outcomes. |
»¨»ï¥¿¥¤¥È¥ë | J Asthma Allergy. 15 |
¥Ú¡¼¥¸ÈÖ¹æ | 1539-1547 |
Ãø¼Ô | Nakanishi Y¡¥ |
¶¦Ãø | Iwamoto H¡¤Miyamoto S¡¤Nakao S¡¤Higaki N¡¤Yamaguchi K¡¤Sakamoto S¡¤Horimasu Y¡¤Masuda T¡¤Matsumoto N¡¤Nakashima T¡¤Onari Y¡¤Fujitaka K¡¤Haruta Y¡¤Hamada H¡¤Hozawa S¡¤Hattori N¡¥ |
¹¹¿·Æü¡§2023/12/29
¿ÇÎÅ²Ê | ¸ÆµÛ´ïÆâ²Ê |
ǯ | 2022 |
ÏÀʸ¥¿¥¤¥È¥ë | Pre-Existing Interstitial Lung Abnormalities Are Independent Risk Factors for Interstitial Lung Disease during Durvalumab Treatment after Chemoradiotherapy in Patients with Locally Advanced Non-Small-Cell Lung Cancer |
»¨»ï¥¿¥¤¥È¥ë | Cancers¡¥14¡Ê24¡Ë |
¥Ú¡¼¥¸ÈÖ¹æ | 6236 |
Ãø¼Ô | Daido W¡¥ |
¶¦Ãø | Masuda T¡¤Imano N¡¤Matsumoto N¡¤Hamai K¡¤Iwamoto Y¡¤Takayama Y¡¤Ueno S¡¤Sumii M¡¤Shoda H¡¤Ishikawa N¡¤Yamasaki M¡¤Nishimura Y¡¤Kawase S¡¤Shiota N¡¤Awaya Y¡¤ Suzuki T¡¤Kitaguchi S¡¤Fujitaka K¡¤Nagata Y¡¤Hattori N¡¥ |
¹¹¿·Æü¡§2023/12/29
¿ÇÎÅ²Ê | ¸ÆµÛ´ïÆâ²Ê |
ǯ | 2022 |
ÏÀʸ¥¿¥¤¥È¥ë | Incidence of venous thromboembolism in advanced lung cancer and efficacy and safety of direct oral anticoagulants: a multicenter¡¤ prospective¡¤ observational study¡ÊRising-VTE/NEJ037 study¡Ë |
»¨»ï¥¿¥¤¥È¥ë | Ther Adv Med Oncol¡¥14 |
Ãø¼Ô | Tsubata Y¡¥ |
¶¦Ãø | Hotta T¡¤Hamai K¡¤Furuya N¡¤Yokoyama T¡¤Saito R¡¤Nakamura A¡¤Masuda T¡¤Hamaguchi M¡¤Kuyama S¡¤Honda R¡¤Senoo T¡¤Nakanishi M¡¤Yamasaki M¡¤Ishikawa N¡¤Fujitaka K¡¤Kubota T¡¤Ohtsu H¡¤Kobayashi K¡¤Isobe T¡¥ |
¹¹¿·Æü¡§2023/12/29
¿ÇÎÅ²Ê | ¸ÆµÛ´ïÆâ²Ê |
ǯ | 2022 |
ÏÀʸ¥¿¥¤¥È¥ë | Switching Treatment from Mepolizumab to Benralizumab for Elderly Patients with Severe Eosinophilic Asthma: A Retrospective Observational Study¡¥ |
»¨»ï¥¿¥¤¥È¥ë | Intern Med¡¥61¡Ê11¡Ë |
¥Ú¡¼¥¸ÈÖ¹æ | 1663-1671 |
Ãø¼Ô | Isoyama S¡¥ |
¶¦Ãø | Ishikawa N¡¤Hamai K¡¤Matsumura M¡¤Kobayashi H¡¤Nomura A¡¤Ueno S¡¤Tanimoto T¡¤Maeda H¡¤Iwamoto H¡¤Hattori N¡¥ |
¹¹¿·Æü¡§2023/12/29
¿ÇÎÅ²Ê | ¸ÆµÛ´ïÆâ²Ê |
ǯ | 2022 |
ÏÀʸ¥¿¥¤¥È¥ë | Phase 2 study of first-line pembrolizumab monotherapy in elderly patients with non-small-cell lung cancer expressing high PD-L1¡¥ |
»¨»ï¥¿¥¤¥È¥ë | ¡¡Thorac Cancer¡¥13¡Ê11¡Ë |
¥Ú¡¼¥¸ÈÖ¹æ | 1663-1671 |
Ãø¼Ô | Masuda T¡¥ |
¶¦Ãø | Fujitaka K¡¤Suzuki T¡¤Hamai K¡¤Matsumoto N¡¤Matsumura M¡¤Isoyama S¡¤Ueno S¡¤Mito M¡¤Yamaguchi K¡¤Sakamoto S¡¤Kawano R¡¤Masuda K¡¤Nishino R¡¤Ishikawa N¡¤Yamasaki M¡¤Hattori N¡¥ |
¹¹¿·Æü¡§2023/12/29
¿ÇÎÅ²Ê | ¸ÆµÛ´ïÆâ²Ê |
ǯ | 2022 |
ÏÀʸ¥¿¥¤¥È¥ë | Effect of baricitinib in patients with coronavirus disease 2019 and respiratory failure: A propensity score-matched retrospective cohort study¡¥ |
»¨»ï¥¿¥¤¥È¥ë | Respir Investig¡¥60(3) |
¥Ú¡¼¥¸ÈÖ¹æ | 418-424 |
Ãø¼Ô | Tanimoto T¡¥ |
¶¦Ãø | Tada S¡¤Fujita S¡¤Hirakawa T¡¤Matsumura M¡¤Isoyama S¡¤Ueno S¡¤Hamai K¡¤Tsuji N¡¤Hirosawa H¡¤Taniguchi T¡¤Okamoto T¡¤Omoto T¡¤Kusunoki S¡¤Maeda H¡¤Ishikawa N¡¥ |
¹¹¿·Æü¡§2023/12/29
¿ÇÎÅ²Ê | ¸ÆµÛ´ïÆâ²Ê |
ǯ | 2022 |
ÏÀʸ¥¿¥¤¥È¥ë | A new risk-assessment tool for venous thromboembolism in advanced lung cancer: a prospective, observational study¡¥ |
»¨»ï¥¿¥¤¥È¥ë | J Hematol Oncol¡¥15(1) |
¥Ú¡¼¥¸ÈÖ¹æ | 40 |
Ãø¼Ô | Tsubata Y¡¥ |
¶¦Ãø | Hotta T¡¤Hamai K¡¤Furuya N¡¤Yokoyama T¡¤Saito R¡¤Nakamura A¡¤Masuda T¡¤maguchi M¡¤Kuyama S¡¤Honda R¡¤Senoo T¡¤Nakanishi M¡¤Yamasaki M¡¤Ishikawa N¡¤Fujitaka K¡¤Kubota T¡¤Kobayashi K¡¤Isobe T¡¥ |
¹¹¿·Æü¡§2023/12/29
¿ÇÎÅ²Ê | ¸ÆµÛ´ïÆâ²Ê |
ǯ | 2022 |
ÏÀʸ¥¿¥¤¥È¥ë | Characteristic computed tomography features in mesenchymal-epithelial transition exon14 skipping-positive non-small cell lung cancer¡¥ |
»¨»ï¥¿¥¤¥È¥ë | BMC Pulm Med¡¥22¡Ê1¡Ë |
¥Ú¡¼¥¸ÈÖ¹æ | 260 |
Ãø¼Ô | Watari N¡¥ |
¶¦Ãø | Yamaguchi K¡¤Terada H¡¤Hamai K¡¤Masuda K¡¤Nishimura Y¡¤Sakamoto S¡¤Masuda T¡¤ ¡¡¡¡Horimasu Y¡¤Miyamoto S¡¤Nakashima T¡¤Iwamoto H¡¤Shoda H¡¤Ishikawa N¡¤Fujitaka K¡¤Miyazaki K¡¤Miyata Y¡¤Hamada H¡¤Awai K¡¤Hattori N¡¥ |
¹¹¿·Æü¡§2023/04/28
¿ÇÎÅ²Ê | ¸ÆµÛ´ïÆâ²Ê |
ǯ | 2021 |
ÏÀʸ¥¿¥¤¥È¥ë | ¼¨¤·µÞ®¤Ë¸ÆµÛÉÔÁ´¤¬¿Ê¹Ô¤·¤¿ÆÃȯÀ´ï¼Á²½ÇÙ±ê¤Î°ìÎã |
»¨»ï¥¿¥¤¥È¥ë | ¸üÀ¸Ï¢ÈøÆ»Áí¹çɱ¡°åÊó¡¡31 |
¥Ú¡¼¥¸ÈÖ¹æ | 79¡Ý84 |
Ãø¼Ô | ¡ÊÆâÆ£¿¾¼¡Ë |
¶¦Ãø | ¡ÊËÌÅç¿¿µª»Ò¡Ë¡¤¡Ê±öëºéÀé»Ò¡Ë¡¤ÎëÌÚÊþ»Ò¡¤¡ÊÀ¾Åĸ»Ê¡Ë |
¹¹¿·Æü¡§2023/04/28
¿ÇÎÅ²Ê | ¸ÆµÛ´ïÆâ²Ê |
ǯ | 2021 |
ÏÀʸ¥¿¥¤¥È¥ë | ¥¹¥Æ¥í¥¤¥ÉÃæ»ß¸å¤ËºÆȯ¤·¤¿ Pulmonary Hyalinizing Granuloma ¤Î£±Îã |
»¨»ï¥¿¥¤¥È¥ë | ¸üÀ¸Ï¢ÈøÆ»Áí¹çɱ¡°åÊó¡¡31 |
¥Ú¡¼¥¸ÈÖ¹æ | 15¡Ý19 |
Ãø¼Ô | ¡ÊËÌÅç¿¿µª»Ò¡Ë |
¶¦Ãø | ¡Ê±öëºéÀé»Ò¡Ë¡¤Ìî¼¹¸À¸¡¤ËÌÅçÂó¿¿¡¤Àîºê¹Ê¿¡¤ÎëÌÚÊþ»Ò¡¤»³ÌÚ¡¡¼Â¡¤¡ÊÀ¾Åĸ»Ê¡Ë |
¹¹¿·Æü¡§2023/04/28
¿ÇÎÅ²Ê | ¸ÆµÛ´ïÆâ²Ê |
ǯ | 2021 |
ÏÀʸ¥¿¥¤¥È¥ë | ´âÀÊ¢Ëì´â¤¬µ¿¤ï¤ì¤¿·ë³ËÀ¶»Ê¢Ëì±ê¤Î£±Îã |
»¨»ï¥¿¥¤¥È¥ë | ¹Åç°å³Ø¡¡74¡Ê8¡Ë |
¥Ú¡¼¥¸ÈÖ¹æ | 385¡Ý389 |
Ãø¼Ô | ËÌÅçÂó¿¿ |
¶¦Ãø | ¡Ê±öëºéÀé»Ò¡Ë¡¤Ìî¼¹¸À¸¡¤¡ÊËÌÅç¿¿µª»Ò¡Ë¡¤Àîºê¹Ê¿¡¤ÎëÌÚÊþ»Ò¡¤¡ÊË̺ꡡľ¡Ë,ÊƸ¶½¤¼£ |
¹¹¿·Æü¡§2023/04/28
¿ÇÎÅ²Ê | ¸ÆµÛ´ïÆâ²Ê |
ǯ | 2021 |
ÏÀʸ¥¿¥¤¥È¥ë | ¤Ú¥à¥Ö¥í¥ê¥º¥Þ¥Ö¤Ë¤è¤ë MPO-ANCA ÍÛÀ¤ÎÇÙ˦½Ð·ì¤Î£±Îã |
»¨»ï¥¿¥¤¥È¥ë | Æü¸ÆµÛ»ï¡¡10¡Ê3¡Ë |
¥Ú¡¼¥¸ÈÖ¹æ | 283¡Ý287 |
Ãø¼Ô | ¡ÊËÌÅç¿¿µª»Ò¡Ë |
¹¹¿·Æü¡§2023/04/28
¿ÇÎÅ²Ê | ¸ÆµÛ´ïÆâ²Ê |
ǯ | 2021 |
ÏÀʸ¥¿¥¤¥È¥ë | Aspergillosis-Associated Pulmonary Oxalosis Successfully Treated with Corticosteroid Therapy: A Case Report |
»¨»ï¥¿¥¤¥È¥ë | ¸üÀ¸Ï¢ÈøÆ»Áí¹çɱ¡°åÊó¡¡31 |
¥Ú¡¼¥¸ÈÖ¹æ | 21¡Ý25 |
Ãø¼Ô | ¡ÊShioya S¡Ë |
¶¦Ãø | Nomura A¡¤¡ÊKitajima M¡Ë¡¤Kitajima T¡¤Kawasaki K¡¤Suzuki T¡¤Yonehara S |
¹¹¿·Æü¡§2023/04/28
¿ÇÎÅ²Ê | ¸ÆµÛ´ïÆâ²Ê |
ǯ | 2021 |
ÏÀʸ¥¿¥¤¥È¥ë | IL-18 binding protein can be a prognostic biomarker for idiopathic pulmonary fibrosis |
»¨»ï¥¿¥¤¥È¥ë | PLoS One¡¥16(6¡Ë |
¥Ú¡¼¥¸ÈÖ¹æ | e0252594 |
Ãø¼Ô | Nakanishi Y |
¶¦Ãø | Horimasu Y¡Ë¡¤¡ÊYamaguchi K¡Ë¡¤¡ÊSakamoto S¡Ë¡¤¡ÊMasuda T¡Ë¡¤¡ÊNakashima T¡Ë¡¤¡ÊMiyamoto S¡Ë¡¤¡ÊIwamoto H¡Ë¡¤¡ÊOhshimo S¡Ë¡¤¡ÊFujitaka K¡Ë¡¤¡ÊHamada H¡Ë¡¤¡ÊHattori N¡Ë |
¹¹¿·Æü¡§2016/02/01
¿ÇÎÅ²Ê | ¸ÆµÛ´ïÆâ²Ê |
ǯ | 2015 |
ÏÀʸ¥¿¥¤¥È¥ë | ½Ñ¸åÉÂÍý¸¡ºº¤Ë¤Æ¿ÇÃǤµ¤ì¤¿ÇÙ¥¤¥Ì»å¾õÃî¾É |
¥Ú¡¼¥¸ÈÖ¹æ | 76¡Ý79 |
Ãø¼Ô | ÃÝ°æÂçÍ´ |
¶¦Ãø | »³ÌÚ¡¡¼Â¡¤Â§¹ÔÉÒÀ¸¡¤ÃݸµÍºµª¡¤²ÏÅççýÀ¡¡¤óîƣε½õ¡¤º´¡¹ÅÄãÀ®¡¤µÈÅÄ¡¡À¿¡¤Å·Ìî¿ÒĪ¡¤Ê¡ÅÄÉÒ¾¡¡¤Ã渶²í¹À¡¤±×ÅÄ¡¡·ò |
¹¹¿·Æü¡§2011/05/01
¿ÇÎÅ²Ê | ¸ÆµÛ´ïÆâ²Ê |
ǯÅÙ | 2011 |
ÏÀʸ¥¿¥¤¥È¥ë | Change in serum KL-6 level from baseline is useful predicting life-threatening EGFR-TKIs induced interstitial lung disease |
»¨»ï¥¿¥¤¥È¥ë | Respir Res |
¥Ú¡¼¥¸ÈÖ¹æ | 26, 97 |
Ãø¼Ô | (Kawase S) |
¶¦Ãø | (Hattori N),(Ishikawa N),(Horimasu Y),(Fujitaka K), Furonaka O, (Isobe T),(Miyoshi S),(Hamada H),(Yamane T),(Yokoyama A),(Kohno N) |
¹¹¿·Æü¡§2011/05/01
¿ÇÎÅ²Ê | ¸ÆµÛ´ïÆâ²Ê |
ǯÅÙ | 2011 |
ÏÀʸ¥¿¥¤¥È¥ë | ٨ʿ¾åÈé´â¤ò½ü¤¯È󾮺Ù˦ÇÙ´â¤ËÂФ¹¤ë¥Ù¥Ð¥·¥º¥Þ¥ÖÎÅË¡¤ÎŬ±þ´ð½à¤Ë´Ø¤¹¤ë¸¡Æ¤ |
»¨»ï¥¿¥¤¥È¥ë | ¹Åç°å³Ø |
¥Ú¡¼¥¸ÈÖ¹æ | 173-176 |
Ãø¼Ô | É÷ϤÃ潤 |
¶¦Ãø | ¼ÂÌÊ·Ä¡¢Âç·îÂëɧ |
- ¾Ã²½´ïÆâ²Ê
- ½Û´Ä´ïÆâ²Ê
- ¸ÆµÛ´ïÆâ²Ê
- ¿Õ¡Æâ²Ê
- ¾®»ù²Ê
- Æâ»ë¶À³°²Ê
- ¿´Â¡·ì´É³°²Ê
- ¸ÆµÛ´ï³°²Ê
- À°·Á³°²Ê
- Ǿ¿À·Ð³°²Ê
- ÈéÉæ²Ê
- ÈçÇ¢´ï²Ê
- ¼ªÉ¡°ö¹¢²Ê
- Ëã¿ì²Ê
- ´ã²Ê
- »ºÉؿͲÊ
- Êü¼ÍÀþ²Ê
- µßµÞ²Ê
- Áí¹ç¿ÇÎŲÊ
- »õ²Ê¸ý¹Ð³°²Ê
- ´ËÏÂ¥±¥¢Æâ²Ê
- Àº¿À¿À·Ð²Ê
- ¾®»ù³°²Ê
- ´ËÏÂ¥±¥¢³°Íè
- Î×¾²¸¦½¤²Ê
- ÉÂÍý¸¦µæ¸¡ºº²Ê
- °å»ö²Ý
- ¾ðÊó´ë²è²Ý
- ²½³ØÎÅË¡¥»¥ó¥¿¡¼
- °åÎÅÊ¡»ã»Ù±ç¥»¥ó¥¿¡¼
- ±ÉÍÜ¥µ¥Ý¡¼¥È¥Á¡¼¥à¡ÊNST¡Ë
- ÌôºÞ²Ê
- ´Ç¸î²Ê
- Êü¼ÍÀþ²Ê(°åÎŵ»½ÑÉôÌç)
- Î×¾²¹©³Ø²Ê
- ¥ê¥Ï¥Ó¥ê¥Æ¡¼¥·¥ç¥ó²Ê
- Î×¾²¸¦µæ¸¡ºº²Ê
- ±ÉÍܲÊ
´Ç¸î²Ê¤Î¤´°ÆÆâ
- ´Ç¸î²Ê¥Ú¡¼¥¸TOP ÈøÆ»Áí¹çɱ¡´Ç¸î²Ê¤Ç¤Î³èÆ°ÆâÍƤȤ´Êó¹ð¤Ç¤¹¡£ÀìÌç³Ø¹»¾ðÊó¤Ê¤É¡£
¤¬¤ó¿ÇÎÅÏ¢·ÈµòÅÀɱ¡
- ÈøÆ»Áí¹çɱ¡¤¬¤ó¾ðÊó ¤¬¤ó¤Ë¤Ä¤¤¤Æ¤ÎÀâÌÀ¤ä¥Ç¡¼¥¿Åù¡¢¤¬¤ó¤Ë¤Ä¤¤¤Æ¤Î¾ðÊó¤Ç¤¹¡£
¤¬¤ó¿ÇÎÅÏ¢·ÈµòÅÀɱ¡
- 繤¬¤ó¥×¥í¥¸¥§¥¯¥È ¤¹¤¤Â¡¡¦´Î¡¤¬¤ó¶µ¼¼¤Î»ñÎÁ
